METHODS: Totally 120 patients(120 eyes)from our hospital from October 2014 to November 2017 were selected as subjects, and randomly divided into 2 groups. Sixty patients(60 eyes)in the conventional group were treated with 25G vitrectomy alone. Sixty patients(60 eyes)in the study group were treated with ranibizumab adjuvant 25G vitrectomy. The patients were followed up for 6mo. The duration of operation, intraoperative and postoperative conditions, postoperative complications, and the BCVA, intraocular pressure, central area of the macula in preoperative and postoperative 6mo were compared.

RESULTS: The average duration of surgery in the study group was significantly lower than that in the conventional group(t=5.727, P<0.05). The incidence of postoperative high intraocular pressure, electrocoagulation hemostasis, iatrogenic retinal tears, and INV(iris neovascularization)were significantly lower in the study group than in the conventional group(P<0.05), the overall incidence was significantly lower than the conventional group(5.0% vs 16.7%, χ2=4.227, P<0.05). The intraocular pressure and the thickness of the central area of the macula of the study group was significantly lower than that of the conventional group at 6mo after operation, the BCVA was significantly better than the conventional group(t=3.362, 2.486, 8.028, all P<0.05).

CONCLUSION: PDR patients treated with ranibizumab-assisted 25G vitrectomy can effectively shorten the operation time, improve macular edema, reduce the incidence of postoperative bleeding and complications, and be safe and reliable.